Endocrine Abstracts

Background: The anti-hyperglycemic effects of thiazolidinedione/biguanide combination therapy are well established. However, the impact of such therapy on other clinical risk factors for cardiovascular disease (CVD) has not been extensively reported.Objective: To evaluate the anti-hyperlipidemic effects of pioglitazone (PIO) and rosiglitazone (ROSI) used in combination with metformin (MET) in patients with type 2 diabetes, a multicenter, retrospective, r...

Background: The anti-hyperglycemic effects of thiazolidinedione/biguanide combination therapy are well established. However, the impact of such therapy on other clinical risk factors for cardiovascular disease (CVD) has not been extensively reported.Objective: To evaluate the anti-hyperlipidemic effects of pioglitazone (PIO) and rosiglitazone (ROSI) used in combination with metformin (MET) in patients with type 2 diabetes, a multicenter, retrospective, r...

Risk of cardiovascular disease is higher for patients with diabetes and dyslipidemia. Known risk factors include elevated triglycerides (TG), total cholesterol (TC), LDL, and low HDL. The log(TG: HDL), known as Atherogenic Index of Plasma (AIP), is inversely correlated with LDL particle size (r=-0.78) and provides another marker of coronary heart disease (CHD) risk. Low-risk CHD cohorts have negative AIP values; high-risk cohorts have positive values. Patients with type 2 diab...